LEI105 is a potent, highly selective, and reversible dual inhibitor of diacylglycerol lipase-α (DAGL-α) and DAGL-β; it reduces 2-arachidonoylglycerol levels in Neuro2A cells and attenuates cannabinoid CB1 receptor-mediated short-term synaptic plasticity in mouse hippocampal slice models; it shows potential for research in obesity, related metabolic disorders, and neuroinflammatory diseases.